Decline in Baby Aspirin Use for Heart Disease Prevention Reflects Changing Guidelines
Recent data from Epic Research indicates a significant decline in the use of daily baby aspirin for heart disease prevention among adults. The study analyzed over 270 million patient encounters and found that the use of low-dose aspirin fell from 7.2% in 2018 to 3.2% by 2025. This trend aligns with updated guidelines from the U.S. Preventive Services Task Force (USPSTF) and other health organizations, which have revised their recommendations based on new evidence. Previously, baby aspirin was widely recommended for adults aged 50 to 59 with a 10% or higher risk of cardiovascular disease, provided they were not at increased risk of bleeding. However, recent studies have shown that the benefits of aspirin in preventing cardiovascular events are not as significant as once thought, and the risks, such as increased bleeding, are more pronounced. Consequently, the American College of Cardiology and the American Heart Association now advise against its use for primary prevention in most adults. 
